Superficial radiation therapy provider Sensus Healthcare said it has made the 100th sale of its SRT-100 device for treating nonmelanoma skin cancers.
The milestone customer was Froedtert and the Medical College of Wisconsin, Sensus said. This was the company's first sale in Wisconsin.
Sensus has also received clearance from China's State Food and Drug Administration (SFDA) to market and sell SRT-100 in China.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
